PNC Financial Services Group
TOVX icon

PNC Financial Services Group’s Theriva Biologics TOVX Stock Holding History

PNC Financial Services Group’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1
Closed -$29K – 4700
2015
Q2 		$29K Buy
+1
New +$20.1K ﹤0.01% 3326
2014
Q4 		– Hold
0
– -$5K – 4254
2014
Q3 		– Hold
0
– – – 3465

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PNC Financial Services Group's TOVX Position: Q3 2015 in Review

PNC Financial Services Group sold out of Theriva Biologics (TOVX) in Q3 2015, closing a stake of 1 share — an estimated $29K sold.

PNC Financial Services Group first reported a position in TOVX in Q2 2015 and held it in 1 quarter. The position peaked at $29K in Q2 2015. 45 funds tracked by Wall St. Rank hold TOVX as of Q3 2015.

  • PNC Financial Services Group reported no remaining Theriva Biologics position as of Q3 2015 after selling out during the quarter.
  • PNC Financial Services Group sold 1 Theriva Biologics share in Q3 2015, an estimated $29K.
  • PNC Financial Services Group first reported a position in Theriva Biologics in Q2 2015 and held it in 1 quarter.
  • PNC Financial Services Group's Theriva Biologics position peaked at $29K in Q2 2015.
  • 45 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2015.

Based on PNC Financial Services Group's 13F filing for Q3 2015, filed 6 Nov 2015.